Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China's Health Care Market Draws Healthy Investment

This article was originally published in PharmAsia News

Executive Summary

Hospital investment and management firm Hua Xia Healthcare Holdings announced that it has put aside funds to acquire 10 private hospitals this year. The company spoke to more than 100 international health care investment organizations in 2007 and found that at least $60 billion capital has been earmarked for China. International Finance Corp., a member of World Bank Group, estimated it invested $700 million in China's hospitals last year. Four health-related enterprises, including Fosun Pharma, received loan support totaling $870 million. Eplanet Ventures plans to complete its second round of fund raising that invests mainly in the health care market in India and China. Domestic investors also see China's market opportunities; Shunde private capitalists have funded an 800 million yuan private hospital that began construction in Guangdong last year. (Click here for more - Chinese Language)

You may also be interested in...

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Adolescents In COVID-19 Vaccine Trials: As Pfizer Starts Dosing, US FDA Encouraging Other Sponsors

But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts